A New Influenza Vaccine: First Phase Has Passed
First phase clinical trials of innovative trivalent recombinant influenza vaccine developed by NANOLEK in cooperation with FBUN GNC VB Vector Rospotrebnadzor (Novosibirsk) has been completed.
A double-blind placebo-controlled multicenter clinical study of tolerability and safety of the vaccine has been completed. The study included volunteers of 18 to 60 years. None of them had vaccination-related adverse events. Clinical and biochemical test changes in real-time mode variated within the normal physiological range. Baseline parameters versus follow-up values after vaccination were within the normal range. No deviations in the neurological status were observed.
The key benefit of the vaccine was that it was free of allergizing effects.
The results enable continuation of clinical studies of the vaccine to assess its immunogenicity and safety.